The study highlights poor outcomes for leukaemia patients with a history of myelodysplastic syndrome treatment and related ...

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

In the current study, researchers compared survival among their patients with other patients with AML, finding no notable differences in event-free survival (EFS) or overall survival (OS ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Aptose Biosciences (APTO) announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib in combination with ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

About the Phase 1 First-in-human Study of LAVA-1266 (ACTRN12624001214527) ...